Current Activities

No.
Title
TGOG-1004
Cervical adenocarcinoma & adenosquamous carcinoma.
TGOG-1005
An open, randomized, multi-center phase 2 trial of Tamoxifen and Letrozole in recurrent or persistent squamous cell carcinoma of the cervix.
TGOG-1006
(AGOG13-001 Cooperative study):Verification of HPV16 as a good prognostic factor for cervical adeno-adenosquamous carcinoma: An international collaborative study.
TGOG-1007
(KGOG1209 Cooperative study):A randomized controlled trial comparing radical hysterectomy plus tailored adjuvant therapy versus primary chemoradiation therapy in bulky early-stage cervical cancer.
TGOG-1008
(AGOG14-001 Cooperative study):A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer.
TGOG-1009
Randomized, Double blind, Placebo-controlled Trial of Z-100 plus Radiation Therapy in Patients with Locally Advanced Cervical Cancer — A Phase III trial.
TGOG-2005
The adjuvant management of FIGO stage IIIA-IVB uterine endometrioid adenocarcinoma: a multi-center, retrospective study.
TGOG-2006
Necessity of Radical Hysterectomy for endometrioid Endometrial Cancer with cervical stromal involvement ? a retrospective study Taiwan Gynecologic Oncology Group
TGOG-2007
Mirena® ± metformin as Fertility-preserving Treatment for Young Asian Women with Early Endometrial Cancer 
TGOG-3006 A retrospective review of clinical presentation, and prognosis of the malignant transformation in mature teratoma of the ovary- Multiple Medical Center Cooperation Study in Taiwan Gynecologic Oncology Group.
TGOG-3008 (AGOG Cooperative study)A phase II trial of postoperative platinum-based chemotherapy plus adjuvant and maintenance bevacizumab after neoadjuvant chemotherapy followed by interval surgery in patients with extensive stage IIIC or IV ovarian, tubal, and peritoneal cancer
TGOG-3009 (GOTIC-001 / JGOG3019 Cooperative study) A Randomized Phase II/ III   
Trial Of Intravenous (Iv) Paclitaxel Weekly Plus IV Carboplatin Once Every 3 Weeks Versus IV Paclitaxel Weekly Plus Intraperitoneal (IP) Carboplatin Once Every 3 Weeks In Women With Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Cancer. 
TGOG-5001 A randomized, double blind, placebo-controlled study to assess the efficacy and safety of eltrombopag as a rescue of isolated chemotherapy-induced thrombocytopenia in patients with gynecologic cancer
TGOG-5002 The role of bevacizumab in refractory gynecologic cancers